GlassScriptPhysician profile
Megan A Offray
NPI 1316350150
$8,260.86
in general payments reported to CMS, 2019-2025
24 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $1,482 · 2023: $2,459 · 2024: $2,044 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,090 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,090.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Education | $272.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,026.83 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $1,016.59 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $966.48 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $955.66 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $617.63 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $592.79 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Janssen Biotech, INC. | $549.17 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $440.02 | 2022-2025 | |
| Genzyme Corporation | $365.64 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $300.19 | 2022-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $268.59 | 2022-2025 | Jublia, Arazlo, Cabtreo |
| Ucb, INC. | $227.70 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $209.09 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $160.99 | 2022-2025 | Sotyktu |
| Pfizer INC. | $140.67 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $123.18 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $83.05 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $64.88 | 2023-2024 | Vtama |
| Almirall LLC | $55.69 | 2025 | Klisyri |
| Epi Health, LLC | $31.57 | 2022 | |
| Botanix Sb INC | $18.80 | 2025 | Sofdra |
| Journey Medical Corporation | $15.72 | 2022 | |
| Biofrontera INC. | $15.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Offray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.